InNexus Biotechnology Welcomes Dr. Ronald Levy,Stanford University School of Medicine Oncology...

BRITISH COLUMBIA, Canada -- InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL[TM]) technology, welcomes Dr. Ronald Levy to its Scientific

Dr. Levy has had strong ties with Stanford University since receiving his MD from the institution in 1968 and currently serves as the Stanford University School of Medicine Chief of the Division of Oncology, a position he has enjoyed since 1993. Among his many honors and awards, Dr. Levy has been the recipient of the Damashek Prize from the American Society of Hematology, the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center, the Evelyn Hoffman Memorial Award from the Lymphoma Research Foundation of America, and the Key to the Cure Award from the Cure For Lymphoma Foundation. Dr. Levy received his AB in Biochemistry from Harvard University and is the author of more than 250 articles that have appeared in various publications and peer-reviewed journals.

"We have known Dr. Levy for a long time and have been looking for ways in which we could incorporate his strengths into our InNexus team," said InNexus Chairman and CEO, Jeff Morhet. "We are delighted to welcome him to the Scientific Advisory Board, and are even more excited about his contribution in guiding the development of medicines for the treatment of cancer and other hard-to-treat diseases."

"I am pleased to be a member of InNexus' Scientific Advisory Board," said Dr. Levy. "I look forward to contributing to the many innovations and technologies InNexus is bringing to the study of antibody development."

About DXL[TM] Technology

DXL[TM] technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. This may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. In addition, DXL[TM] antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance. To learn more about InNexus' DXL[TM] technology, please visit www.ixsbio.com.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL[TM]) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL[TM] antibodies utilize unique, novel, and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus or the InNexus Scientific Advisory Board, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.